Restrictions on Obesity Drug Coverage Force Patients to Pivot

Why It Matters

The erosion of obesity‑drug coverage threatens patient health outcomes and accelerates out‑of‑pocket spending, pressuring employers and insurers to rethink benefit designs amid soaring GLP‑1 prices.

Key Takeaways

• 12 M lost Zepbound coverage; 12 M lost Wegovy coverage
• 88% of covered patients face prior‑auth or BMI restrictions
• Employer formulary shifts drive premium hikes of ~20%
• Compounded GLP‑1 alternatives cost $300/month vs $450 brand price
• Only ~36% of employers offered GLP‑1 coverage in 2025

Pulse Analysis

The rapid adoption of GLP‑1 agonists for weight loss has created a pricing shockwave across the U.S. health‑care system. Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy command list prices that exceed $1,000 per month, prompting insurers to tighten formularies. By leveraging competition, pharmacy‑benefit managers like CVS Caremark aim to curb spend, but the resulting exclusions leave millions of patients exposed to high out‑of‑pocket costs and jeopardize adherence.

For patients, the impact is immediate and personal. GoodRx’s analysis, based on MMIT data covering over 190 million lives, reveals that 12 million individuals lost Zepbound coverage and another 12 million lost Wegovy in just one year. Even when coverage remains, 88% of enrollees confront prior‑authorization hurdles or restrictive BMI thresholds far above the clinical obesity definition. Employers feel the pressure too; premium hikes of roughly 20% have been directly linked to the expense of GLP‑1 drugs, while only about a third of firms now include these therapies in their benefit packages.

The industry is scrambling for workarounds. Compounded versions of GLP‑1 agents, though not FDA‑approved, offer a lower cash price—about $300 a month versus $450 for brand‑name Zepbound—but they raise safety and supply‑chain concerns. Policymakers and payers are debating broader reforms, from value‑based pricing to standardized coverage criteria, to balance innovation with affordability. Until a sustainable pricing model emerges, patients and providers will continue to navigate a fragmented landscape where medical decisions are increasingly dictated by insurance economics.